123 related articles for article (PubMed ID: 31227776)
1. Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.
Herr MM; Torka P; Zhang Y; Wallace PK; Tario JD; Repasky EA; Chen GL; Ho CM; Balderman SR; Ross M; Paiva B; Hernandez-Ilizaliturri FJ; McCarthy PL; Hahn T
Bone Marrow Transplant; 2020 Jan; 55(1):77-85. PubMed ID: 31227776
[TBL] [Abstract][Full Text] [Related]
2. High Proliferating Regulatory T Cells Post-Transplantation Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation.
Sumransub N; Cao Q; Wangen R; Brunstein C; Miller JS; Bachanova V
Transplant Cell Ther; 2022 Apr; 28(4):184.e1-184.e8. PubMed ID: 35081473
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O; Churnetski MC; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast MA; Fenske TS; Narayana Rao Gari S; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns TF; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
J Clin Oncol; 2019 Feb; 37(6):471-480. PubMed ID: 30615550
[TBL] [Abstract][Full Text] [Related]
4. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
5. Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma.
Savani M; Gencturk M; Shanley R; Cayci Z; Wilke C; Warlick ED; He F; Janakiram M; Weisdorf DJ; Brunstein CG; Bachanova V
Biol Blood Marrow Transplant; 2020 Feb; 26(2):272-277. PubMed ID: 31669174
[TBL] [Abstract][Full Text] [Related]
6. Mantle Cell Lymphoma: Which Patients Should We Transplant?
Gerson JN; Barta SK
Curr Hematol Malig Rep; 2019 Aug; 14(4):239-246. PubMed ID: 31218478
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
[TBL] [Abstract][Full Text] [Related]
8. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.
Shindiapina P; Pietrzak M; Seweryn M; McLaughlin E; Zhang X; Makowski M; Ahmed EH; Schlotter S; Pearson R; Kitzler R; Mozhenkova A; Le-Rademacher J; Little RF; Akpek G; Ayala E; Devine SM; Kaplan LD; Noy A; Popat UR; Hsu JW; Morris LE; Mendizabal AM; Krishnan A; Wachsman W; Williams N; Sharma N; Hofmeister CC; Forman SJ; Navarro WH; Alvarnas JC; Ambinder RF; Lozanski G; Baiocchi RA
Front Immunol; 2021; 12():700045. PubMed ID: 34539628
[TBL] [Abstract][Full Text] [Related]
9. Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.
El-Asmar J; Rybicki L; Bolwell BJ; Kharfan-Dabaja MA; Dean R; Hamilton BK; Hanna R; Jagadeesh D; Kalaycio M; Pohlman B; Sobecks R; Hill BT; Majhail NS
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2522-2526. PubMed ID: 31525493
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.
Procházka V; Gawande RS; Cayci Z; Froelich JW; Cao Q; Wilke C; Dusenbery K; Weisdorf DJ; Bachanova V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):64-70. PubMed ID: 28942016
[TBL] [Abstract][Full Text] [Related]
12. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
14. Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival.
Glimelius I; Smedby KE; Albertsson-Lindblad A; Crowther MJ; Eloranta S; Jerkeman M; Weibull CE
Blood Adv; 2021 Mar; 5(6):1638-1647. PubMed ID: 33710334
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
Maziarz RT; Wang Z; Zhang MJ; Bolwell BJ; Chen AI; Fenske TS; Freytes CO; Gale RP; Gibson J; Hayes-Lattin BM; Holmberg L; Inwards DJ; Isola LM; Khoury HJ; Lewis VA; Maharaj D; Munker R; Phillips GL; Rizzieri DA; Rowlings PA; Saber W; Satwani P; Waller EK; Maloney DG; Montoto S; Laport GG; Vose JM; Lazarus HM; Hari PN
Br J Haematol; 2013 Sep; 162(5):648-56. PubMed ID: 23829536
[TBL] [Abstract][Full Text] [Related]
16. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
17. Blood graft composition after plerixafor injection in patients with NHL.
Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
[TBL] [Abstract][Full Text] [Related]
18. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
20. [Stem cell harvesting after plerixafor treatment].
Hansen PB; Gaarsdal E
Ugeskr Laeger; 2009 Nov; 171(47):3452-3. PubMed ID: 19925734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]